oppn parties A Setback For The AstraZeneca-Oxford University Covid Vaccine

News Snippets

  • NCLT initiates bankruptcy proceedings against former Videocon chairman Venugopal Dhoot for defaulting on loans of Rs 6158cr as personal guarantor in two group companies
  • LIC approves 1:1 bonus share issue
  • Gold and silver futures also go down by 0.7% and 2.2% respectively
  • Stocks tumbled again on Monday as crude prices rose: Sensex went down by 703 points and Nifty by 207 points
  • Supreme Court refuses to cancel the land-for-jobs FIR against Lalu Prasad
  • The spectre of El Nino haunts India: IMD predicts 'below normal ' monsoon this year
  • Labour protest over increase in wages by 35% (as per Haryana example) turns violent in Noida, nearly 200 were detained by the police
  • Congress leader Sonia Gandhi said that the delimitation exercise must be carried out after the Census is complete
  • PM Modi says Parliament is on the verge of creating history as the Houses get ready to take up the women's reservation bills
  • Tata Sons chairman N Chandrasekaran said that TCS COO Aarthi Subramanian is conducting a thorough inquiry to establish facts and identify individuals involved in the sexual harassment allegations at the company's Nashik office
  • Asha Bhonsle laid to rest with full state honours on Monday in Mumbai
  • AAP leader Arvind Kejriwal once again approached the Delhi HC to request the recusal of a judge from his case
  • Candidates Chess: R Vaishali on the verge of creating history, but needs two wins - one with black pieces - against formidable opponents to emerge as the challenger
  • Rohit Sharma, who retired hurt in the match versus RCB, underwent scans for possible hamstring injury
  • IPL: Abhishek Sharma fails for SRH but Ishan Kishan (91) shines. Then, Vaibhav Sooryavanshi fails for RR and SRH bolwers, especially unheralded Praful Hinge (4 for 24) and Sakib Hussain (4 for 24) win it for SRH. This was the first loss for table-toppers RR
Supreme Court questions Election Commission about SIR SOP and why logical discrepancy was introduced only in Bengal
oppn parties
A Setback For The AstraZeneca-Oxford University Covid Vaccine

By Sunil Garodia
First publised on 2020-09-12 08:47:41

About the Author

Sunil Garodia Editor-in-Chief of indiacommentary.com. Current Affairs analyst and political commentator. Author of Cyber Scams in India, Digital Arrest, The Money Trap and The Human Hack

There are no shortcuts in developing new vaccines or drugs. This fact was forcefully brought in focus when AstraZeneca and Oxford University suspended the ongoing Phase 3 trials of their Covid vaccine after a volunteer in the UK developed inflammation in her spinal cord. Serum Institute, which was conducting the trials for the said vaccine in India and was getting ready to produce it on a huge scale, has also stopped the trials. This also shows that the race to develop the vaccine is unholy, especially the US announcement that the vaccine will be available for mass administration from the first week of November.

The coronavirus pandemic has brought untold miseries upon the human race. It has brought economies to a standstill and has caused severe loss of production and income due to lockdowns. Governments all over the world are grappling to provide relief to people whose jobs are gone and income is squeezed. In such a scenario, it is important that a vaccine or a drug to treat the disease is developed at the earliest. But does that mean that pharmaceuticals companies, guided by the profit motive, will throw all norms to the wind?

Developing a new vaccine or drug is a long drawn out process and can take anywhere between 9 to 18 months or longer before it can be certified as safe and effective. There are numerous stages of trials. Volunteers are needed for each stage. After every stage, the results need to be collated, studied and submitted for regulatory approvals. The next stage can be started only after approval of the results of the earlier stage. There are no shortcuts.

Although vaccines and drugs for all new diseases have had their share of setbacks and the time taken to release them in the market has many times overshot the initially expected deadline, the Covid vaccine is being awaited expectantly all over the world. Russia has already released one in the market. But all other developers are in various stages of trial. The AstraZeneca-Oxford University was considered a frontrunner. But the unfortunate hiccup in the trails will now be vetted by an independent panel. The trials will resume only after the cause is identified and corrective measures are taken. This effectively pushes the vaccine back by at least three months. In any case, is it not better to receive a safe and effective vaccine later rather than experiment with a half-baked one now, one that can endanger lives?